Article Text

Download PDFPDF

Systematic evaluation of patient-reported outcome (PRO) protocol content and reporting in UK cancer clinical trials: the EPiC study protocol
  1. Khaled Ahmed1,2,
  2. Derek Kyte1,2,
  3. Thomas Keeley1,2,
  4. Fabio Efficace3,
  5. Jo Armes4,
  6. Julia M Brown5,
  7. Lynn Calman6,
  8. Chris Copland7,
  9. Anna Gavin8,
  10. Adam Glaser9,
  11. Diana M Greenfield10,
  12. Anne Lanceley11,
  13. Rachel Taylor12,
  14. Galina Velikova13,
  15. Michael Brundage14,
  16. Rebecca Mercieca-Bebber1,15,
  17. Madeleine T King15,
  18. Melanie Calvert1,2
  1. 1Centre for Patient Reported Outcomes Research (CPROR), University of Birmingham, Birmingham, UK
  2. 2Institute of Applied Health Research, University of Birmingham, Birmingham, UK
  3. 3Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy
  4. 4King's College London, London, UK
  5. 5UKCRC Registered CTU Network, University of Leeds, Leeds, UK
  6. 6Department of Heath Sciences, University of Southhampton, Southampton, UK
  7. 7NCRI Psychosocial Oncology and Survivorship CSG Consumer member, York, UK
  8. 8Queen's University Belfast, Centre for Public Health, Belfast, UK
  9. 9Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, UK
  10. 10Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK
  11. 11University College London, UCL EGA Institute for Women's Health, London, UK
  12. 12University College London Hospital (UCLH), London, UK
  13. 13University of Leeds, Leeds, UK
  14. 14Queen's Department of Oncology School of Medicine, Queen's Cancer Research Institute, Kingston, Ontario, Canada
  15. 15Faculties of Science and Medicine, University of Sydney, Sydney, New South Wales, Australia
  1. Correspondence to Dr Derek Kyte; d.g.kyte{at}bham.ac.uk

Abstract

Introduction Emerging evidence suggests that patient-reported outcome (PRO)-specific information may be omitted in trial protocols and that PRO results are poorly reported, limiting the use of PRO data to inform cancer care. This study aims to evaluate the standards of PRO-specific content in UK cancer trial protocols and their arising publications and to highlight examples of best-practice PRO protocol content and reporting where they occur. The objective of this study is to determine if these early findings are generalisable to UK cancer trials, and if so, how best we can bring about future improvements in clinical trials methodology to enhance the way PROs are assessed, managed and reported. Hypothesis: Trials in which the primary end point is based on a PRO will have more complete PRO protocol and publication components than trials in which PROs are secondary end points.

Methods and analysis Completed National Institute for Health Research (NIHR) Portfolio Cancer clinical trials (all cancer specialities/age-groups) will be included if they contain a primary/secondary PRO end point. The NIHR portfolio includes cancer trials, supported by a range of funders, adjudged as high-quality clinical research studies. The sample will be drawn from studies completed between 31 December 2000 and 1 March 2014 (n=1141) to allow sufficient time for completion of the final trial report and publication. Two reviewers will then review the protocols and arising publications of included trials to: (1) determine the completeness of their PRO-specific protocol content; (2) determine the proportion and completeness of PRO reporting in UK Cancer trials and (3) model factors associated with PRO protocol and reporting completeness and with PRO reporting proportion.

Ethics and dissemination The study was approved by the ethics committee at University of Birmingham (ERN_15-0311). Trial findings will be disseminated via presentations at local, national and international conferences, peer-reviewed journals and social media including the CPROR twitter account and UOB departmental website (http://www.birmingham.ac.uk/cpro0r).

Trial registration number PROSPERO CRD42016036533.

  • PROs
  • Quality of life
  • CONSORT PRO
  • SPIRIT Checklist
  • Evaluation
  • Cancer trials

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.